Latest: FDA Approves New Biosimilar for Oncology Treatment
Oncology

Treatment Options and Patient Counseling at Disease Progression in IDH-Mutant Gliomas

by Cancer Network
0 Comments
0 Mins
Panelists discuss how to manage slow FLAIR progression by initiating IDH inhibitor therapy, emphasizing the importance of setting patient expectations about tumor volume reduction and addressing special considerations for patients of childbearing age.
Tags:
Cancer Network
Author

Cancer Network

Previous Post
Case-Based Approach to Initial Treatment Planning for IDH-Mutant Gliomas
Next Post
STAT+: Pharmalittle: We’re reading about a troubled Novo manufacturing plant, PEPFAR funding and more news
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago